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REVIEW OF THE p53 TUMOR SUPPRESSOR GENE 
AND ITS ROLE IN GLIOMAS 
James Dearing Christian IV 
A thesis submitted in partial fulfillment of the 
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Commonwealth University. 
Virginia Commonwealth University, 1994. 
Major Director: Dr. Randall Merchant, Ph.D. 
Department of Anatomy 
The following review of the p53 tumor suppressor gene 
will be discussed with particular attention to its role in 
human gliomas, as well as the various advances that have 
brought this molecule to the forefront of cancer research. A 
review of tumorigenesis focuses on the molecular mechanisms 
that convey neoplastic characteristics upon a normal cell. It 
is discussed how the coordinate advances in chromosome 
analysis and molecular techniques enabled the p53 gene to be 
categorized as a "tumor suppressor gene" and applied to 
various forms of cancer, including colorectal and lung 
carcinoma. The focus of the review will be on the involvement 
of p53 in gliomas, as the p53 mutation rate in gliomas is 
quite different from that in other cancers. It is also noted 
how cellular characteristics. contribute to the function of 
p53, and how p53 expression indicates grades of tumor 
X 
malignancy, thereby aiding in diagnosis and prognosis. In 
conclusion, future applications of p53 in areas such as gene 
therapy are examined, as well as alternative mechanisms of 
tumor suppression that circumvent direct p53 mutations in 
gliomas. 
Introduction 
Tumors of neuronal or glial cell origin are termed 
neuroepithelial tumors, and they represent fifty to sixty 
percent of primary intracranial tumors (Annegers et al. , 1981; 
Walker, 1985). These cells have their origin from the 
neuroectoderm, which distinguishes their tumors from other 
cancers associated with soft cell tissue (sarcomas) derived 
from the mesoderm. The World Health Organization (WHO) has 
divided gliomas, tumors of glial cell origin, into different 
grades based on their cytological characteristics such as 
degree of cellularity, mitoses, and necrosis. The current 
system uses a three-stage classification method, dividing 
gliomas into astrocytoma, anaplastic astrocytoma (AA), and 
glioblastoma multiforme (GBM) (Okazaki and Scheithauer, 1988). 
There is also a four-stage sytem that has been used for many 
years and divides gliomas into malignancy grades I-IV, with 
grade IV being the most malignant. Due to the prevalence of 
the four-stage system used in the majority of the literature, 
it is this sytem that will be followed in this review. There 
is the Grade I juvenile pilocytic astrocytoma, Grade II 
astrocytoma, Grade III AA, and Grade IV GBM (Okazaki and 
Scheithauer, 1988) . The natural history for those gliomas 
presenting as low grade is that they classically progress to 
l 
high grade tumors. 
occurs is disputed. 
2 
The method by which this progression 
It is possible that GBM develops by 
neoplasia (new growth) from a glioblast cell, but these cells 
have not been found in adults. Therefore, it is more likely 
that GBM develops by anaplasia (loss of differentiation) of 
astrocytes in astrocytomas and then AA's, eventually 
proceeding to GBM (Russell and Rubinstein, 1989}. 
There are several disturbing trends in brain tumor 
incidence, particularly gliomas, that indicate a need for 
immediate attention to this form of cancer. For instance, 
brain tumors seem to be affecting younger populations than was 
originally observed. Brain tumors rank second in cancer 
incidence for children, fifth for adolescents, and €ighth 
among young adults (Beardsley, 1994) . Still, other 
epidemiological statistics indicate that older populations 
show increasing incidence of brain tumors as well (Marantz and 
Walsh, 1994). Also, there is no known etiology for brain 
tumors, as skin cancer is causally associated with sun 
exposure and lung cancer with smoking. Of adult 
neuroepithelial tumors, GBM is the most commonly occurring at 
initial diagnosis, accounting for approximately fifty percent 
of the tumors classified as this highest grade glioma 
(Zimmerman 1969; Walker et al., 1985; Green et al., 1976). 
Equally discouraging factors involved with gliomas are the 
limited effective treatment available and short survival 
period. Conventional treatment for GBM, including radical 
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resection and radiation therapy, typically provides a median 
survival of about nine months with less than five percent 
surviving five years after the initial diagnosis (Salcman, 
1990). Adjuvant therapies, including chemotherapy and 
immunotherapy, have not yet been shown to significantly 
increase survival over conventional treatment. Therefore, the 
need for innovative therapies for gliomas is evident. 
The inactivation of the p53 protein is believed to be a 
crucial step in the process of tumorigenesis in many cancers, 
including colorectal, breast, lung, and brain (Nigro et al., 
1989). Due the malignant nature of these cancers, especially 
GBM, the involvement of p53 as a tumor suppressor gene has 
been studied with increased attention. Reintroduction of p53 
into cells deficient for this tumor suppressor gene has been 
shown to largely reverse the malignant phenotype. These 
observations raise the possible utility _ of attempting 
reintroduction as a therapeutic maneuver. In this way, the 
p53 tumor suppressor gene offers a unique opportunity for gene 
therapy treatment of brain tumors and other cancers. The goal 
of this review is to offer insight into the nature of the p53 
tumor suppressor gene and the basis for its potential role in 
the treatment of gliomas. 
Review of Tumorigenesis 
Tumorigenesis is the process by which a normal cell 
deviates from its typical pattern of development and attains 
a distinct cancerous phenotype. Characteristics of this stage 
include uncontrolled growth and invasiveness, with development 
and differentiation also being adversely affected. 
Uncontrolled growth is required for all cancer development, 
while these other qualities apply to specific ones. Cancers 
such as colon, lung, and breast are characterized by their 
metastatic potential, while gliomas are particularly noted for 
their invasiveness. Cells typically develop through signals 
from their extracellular environment, and if the reception of 
these signals is altered, the cells may grow in an abnormal 
manner. In the same way, cells begin to differentiate at a 
certain stage, and if this is negatively affected, a loss of 
differentiation may occur. Cancer formation involves a 
complex array of factors, with potential results that can be 
quite damaging to the normal functions of a cell. 
A selective growth advantage within cancer cells allows 
them to undergo clonal expansion. Tumorigenesis is a 
multistage, stepwise process that involves several genetic 
lesions. In order for the correct mechanisms to occur, there 
must be an interplay between two principal participants, 
4 
including 
genes). 
oncogenes and anti-oncogenes 
The critical interaction is 
5 
(tumor suppressor 
the activation of 
oncogenes by a variety of mechanisms and the inactivation of 
tumor suppressor genes, such as by a single missense mutation 
as with p53. The role of p53 is apparent as each of these 
classes of genes is further examined. 
Oncogenes represent an altered version of proto-oncogenes 
(normal cellular counterparts of oncogenes), and they have the 
ability to transform cells in tissue culture (in vitro) and 
render them tumorigenic in vivo (Cantley et al., 1991; Bishop, 
1991; Hunter, 1991) . Many oncogenes were identified within 
genomes of acutely transforming retroviruses. These viruses 
evolve through genetic recombination such that a mutated 
version of a cellular proto-oncogene is integrated into a 
partially deleted retroviral genome (Bishop, 1983). Oncogenes 
may be activated by a number of different molecular 
mechanisms, including transduction of oncogenes by 
retroviruses, trans location of chromosomes or chromosomal 
segments, gene amplification, deletion of suppressor or 
regulatory genes, and point mutations. The two most common 
mechanisms of oncogene activation'include: 1) mutations of the 
gene itself, the enhancer, promoter, or regulatory gene, which 
result in altered function; 2) displacement of a gene by 
random breakage so that it is downstream of an inappropriate 
promoter, resulting in altered expression. To test the 
identity of a gene as an oncogene, the candidate gene is 
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introduced into a normal cell and if the cell acquires 
cancerous traits, then the introduced gene is an oncogene 
(Bishop, 1985). In order to better understand the role of 
oncogenes in tumorigenesis, it is necessary to examine their 
mechanisms of transformation of normal cells into cancerous 
ones. 
The mechanism of oncogene action relies on its disruption 
of the normal function of proto-oncogenes. A normal cell 
within tissue is predominantly under the control of its 
surroundings, which send various messages that affect the 
cell's growth and division in different ways. These signals 
are conveyed by growth factors and may be growth-stimulatory 
or growth-inhibitory in nature. Proto-oncogenes encode many 
of the proteins in the complex signaling circuitry that 
enables a normal cell to respond to extracellular growth 
factors (Weinberg, 1994). These proteins can include: cell 
surface receptors, cytoplasmic signal transducers, and nuclear 
transcription factors. The nuclear transcription factors, 
upon stimulation from the other proteins, activate the 
cellular genes that coordinate the cell's growth pattern. It 
is from proto-oncogene proteins such as these that the 
oncogenes receive their function, for upon mutation the 
oncogenes are able to express aberrantly functioning versions 
of these proteins. In this way, oncogene proteins can then 
activate the signaling circuits within the cell in the absence 
of stimulation by extracellular growth factors (Weinberg, 
7 
1994). Oncogenes can thereby ceaselessly drive cell growth, 
for the cells divide despite the presence of the appropriate 
signals. However, as a protective mechanism, the creation of 
a cancer cell is more complex, and multiple genetic changes 
must take place for tumorigenesis to occur. Oncogenes are 
only one of the factors needed to complete the process of 
tumorigenesis, as anti-oncogenes (tumor suppressor genes) must 
also be deleted or mutated. 
Tumor suppressor genes have not been studied to the 
extent that oncogenes have, but their importance in the scheme 
of tumor formation is equally apparent. Table 1 offers 
examples of cloned tumor suppressor genes with tumor 
association and chromosome affected. Normal cells possess 
genes that not only stimulate growth as proto-oncogenes do, 
but also act to constrain growth, as is the case with tumor 
suppressor genes. Cells therefore receive not only growth­
stimulatory signals (received by proto-oncogene proteins), but 
also growth-inhibitory signals (received by proteins specified 
by tumor suppressor genes). If the function of the tumor 
suppressor gene is inactivated and therefore its protein 
expression altered, then the cell cannot correctly respond to 
extracellular growth-inhibitory signals. The cells will 
divide continually because there are no proper receptors for 
the negative growth signals to be received and transduced. In 
the case of a cancer cell, the oncogenes become hyperactivated 
versions of the proto-oncogenes, and there is a coordinate 
Table 1. Examples of Cloned Tumor Suppressor Genes 
Tumor Suppressor Tumor 
Gene 
Rb retinoblastoma 
lung carcinoma 
(small-cell) 
osteosarcomas 
p53 carcinomas:colorectal 
NFl 
NF2 
lung 
breast 
leukemias 
gliomas 
neurofibromas 
Schwannomas 
meningiomas 
Chromosome 
Affected 
13ql4 
17pl3.1 
17qll 
22q 
8 
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loss of tumor suppressor gene function due to deletion. In 
effect, a cancer cell's growth may derive from a stuck 
accelerator (an activated oncogene) or a defective braking 
system (inactivated tumor suppressor gene), and both defects 
together are thought to be needed to achieve truly aggressive 
proliferation (Weinberg, 1994). 
An initial model of tumor suppressor genes was proposed 
by Knudson (1969) and subsequently investigated by Friend et 
al. (1986) and Fung et al. (1987) in the study of the 
retinoblastoma (Rb) gene in neuroblastoma. The Rb gene was 
the first tumor suppressor gene cloned and still represents 
the classic example of a tumor suppressor gene. The existence 
of the Rb tumor suppressor gene was originally predicted by a 
statistical study of congenital Rb. Knudson (1971) based his 
proposal on the observations of 48 cases of congenital Rb, a 
cancer of the eye in children, arguing that Rb arises by two 
mutational events. In the dominantly inherited form, the 
first mutation is inherited via germline transmission and the 
second occurs as a spontaneous mutation in somatic cells. In 
the nonhereditary form, two spontaneous mutations must occur 
in somatic cells. His theory about cancer originating in more 
than one discreet stage was original, but the mechanism by 
which cancer could arise in as few as two steps remained 
unclear. 
Friend et al. (1986) first succeeded in cloning the Rb 
gene, after other researchers such as Lee et al. (1987) -had 
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identified the general location of Rb on chromosome 13. Lee 
et al. ( 1987) by cloning and sequence analysis actually 
isolated and sequenced the human Rb susceptibility gene, 
thereby allowing true studies of mutations to be done. It was 
noted from earlier studies that a genetic locus in chromosome 
region 13q14 conferred susceptibility to Rb. on the basis of 
chromosomal location, homozygous deletion, and tumor-specific 
changes in expression, Rb susceptibility gene was identified 
as a 200-Kb gene that encodes a 105-kilodalton (KD) nuclear 
phosphoprotein (Lee et al., 1987). In Rb, there is a 
deletion on the long arm of chromosome 13, with subsequent 
loss or inactivation of the gene. Subsequently, it was shown 
that the Rb gene forms stable complexes with the oncoprotein 
of the ElA adenovirus (Whyte et al., 1988) , the large T 
antigen (the transforming protein of the SV4-0 virus) (Ludlow 
et al., 1989), and the human papillomavirus type 16 E7 
oncoprotein (Dyson et al., 1989). The fact that transforming 
proteins encoded by DNA tumor viruses bind to the Rb-encoded 
protein suggested that these viral proteins may function 
through inactivation of the Rb tumor suppressor gene product. 
Inactivation of both alleles at'the Rb locus during retinal 
development is the primary mechanism of tumorigenesis in this 
cancer. 
The mutant versions of the Rb gene act as "simple 
recessive" alleles (Weinberg, 1994). The gene is present in 
two copies, and if one is lost, cell growth remains normal 
l-1 
based on the remaining gene copy. If the second copy is 
"knocked out", then abnormal proliferation occurs. The 
chances of losing one copy of a gene are as low as one in a 
million per cell generation; the chance of losing both copies 
is less than about one in a billion per cell generation 
(Weinberg, 1994). This Rb tumor suppressor model of recessive 
genetic mechanisms can be contrasted with the "dominant 
negative" effect of p53 in other cancers. In the case of p53, 
the initially mutated gene copy loses its tumor-suppressing 
function by deletion and simultaneously interferes with the 
function of the remaining intact copy (Weinberg, 1994). This 
normal (wild-type) copy may either be deleted entirely or 
replaced with another copy of the mutant version. Therefore, 
the mutant p53 gene adversely affects the functions of the 
normal gene copy, which may result in abnormal growth. In 
this way, the mechanism of inactivation of the Rb gene is 
different from that of p53. 
Nevertheless, other Rb characteristics are quite similar 
to those of p53. In a definitive study by Fung et al. (1993), 
it was shown that inactivation of both alleles of the Rb gene 
by mutation resulted in a predisposition to development of 
this cancer. Furthermore, growth arrest could be reinstated 
by transfection of an exogeneous wild-type Rb gene. Also, the 
inactive Rb gene was shown to be passed down in a familial 
context. These early studies involving the Rb gene enabled 
the eventual p53 model of tumor suppression to be realized. 
Identification of p53 
The discovery of p53 is credited by two different groups 
of experimenters. Lane and Crawford (1979) immunoprecipitated 
a cellular 53-KD nuclear phosphoprotein bound to the large 
transforming T antigen of the SV40 (simian virus 40) DNA tumor 
virus. A closely related study by Linzer and Levine (1979) 
characterized a 54-KD cellular SV40 tumor antigen in SV40-
transformed cells. Originally, it was postulated that perhaps 
the p53 protein could be a viral protein because of its 
interaction with the SV40 DNA virus, but p53 could not be 
found in the viral genome. It was not until the p53 protein 
was found in the nucleus of the cell that subsequent advances 
could be made. Since these experiments, the understanding of 
the role of p53 in the process of tumorigenesis has continued 
to evolve, and it is only recently that p53 has been 
classified as a tumor suppressor gene. It was subsequently 
proposed that p53 was an oncogene because it could cooperate 
with the "ras" oncogene in transformation (Parada et al., 
1984) . It is now known, however, that mutant 
derivatives were used in those early experiments. 
later examined in clones of non-tumor cells. 
p53 gene 
P53 was 
It was 
discovered that the p53 sequence in these non-tumor cells was 
not the same as that previously studied. In fact, experiments 
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proved that wild-type p53 does not associate with "ras" to 
transform primary cells unless a mutation has taken place 
(Hinds et al., 1989). It was then suggested that the p53 in 
normal cells was the wild-type p53, while the mutant p53 was 
associated with the ras oncogene in co-transformation (Hinds 
et al.,1989). Further studies indicated that indeed the p53 
protein could not be an oncogene, for although the mutant form 
was found in tumors, the wild-type protein was found to 
suppress tumor progression (Mercer et al., 1990). It was at 
this time that p53 began to be considered a tumor suppressor 
gene based on its comparisons with the Rb gene model. 
Mutations in a variety of locations on the p53 gene are 
responsible for the transforming potential of the molecule, 
which is coordinated with an inactivation of wild-type p53. 
Mutations of the p53 gene have been noted in a series of 
experiments over the years, but it was not until there was a 
correlation with chromosomal abnormalities associated with a 
variety of cancers that p53 became viewed as a tumor 
suppressor gene. Subsequently, the role of p53 and its 
associated proteins has been studied in many cancers, 
including gliomas. Over time, various characterizations of 
p53 have been made, thereby enabling researchers to better 
understand the true nature of this molecule. 
Association of Cancers with Characteristic Chromosomal and 
Molecular Genetic Abnormalities 
With the advent of chromosome banding techniques in 1970 
by Caspersson and Zech (Mitelman,1994), cancer cytogenetics 
was revolutionized. Each chromosome could be identified on 
the basis of its distinct banding pattern, and all 
descriptions of chromosomal deviations became more precise. 
Hematalogical malignancies and, subsequently during the 
1980's, solid tumors began to be examined for cancer­
associated chromosomal aberrations. Chromosome changes could 
be numerical, where whole chromosomes were added or deleted, 
or structural changes, which involved translocations, 
deletions, inversions, and insertions (Sandberg, 1994). In 
concordance with these cytogenetic breakthroughs, new 
molecular genetic techniques were also discovered that enabled 
researchers to investigate tumor cells at the level of 
individual genes (Mitelman, 1994). 
Advances in molecular genetics were beginning to offer 
insight into the detailed mechanisms of neoplastic behavior. 
Novel molecular analyses included: detection of changes in DNA 
(Restriction Fragment Length Polymorphism (RFLP), Polymerase 
Chain Reaction (PCR) amplification, and Southern Blotting), 
messenger RNA (mRNA) (Northern Blotting), and protein products 
14 
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(Western Blotting) (Sandberg, 1994). Other current advances 
include full sequencing and single-strand conformation 
polymorphism (SSCP}. The instances when particular techniques 
are used are based on the particular aims of the experiment 
and the strengths and weaknesses of each technique. For 
example, in the case of RFLP, a mutation at the restriction 
cut-site or a deletion of a cut fragment will result is 
absence of detection by a probe. SSCP is much more sensitive 
than RFLP because it can detect changes in single base pairs 
as opposed to whole fragments. However, SSCP requires that 
the cells of interest be in a proportion of at least 10% of 
the sample, otherwise they are too diluted to be detected. 
RFLP is particularly effective in detecting loss of 
heterozygosity on chromosomes. Normally, both copies of a 
gene will have different lengths when detected by RFLP; in 
other words, heterozygosi ty is observed. However, if there is 
a mutation of one allele and a subsequent deletion or 
replacement of the other allele with a mutant copy, only one 
band will appear by RFLP. Therefore, loss of heterozygosity 
has occurred and has been detected by RFLP. Advances such as 
these in molecular genetics raise the possibility of aiding in 
more effective diagnosis and prognosis of certain cancers and 
their associated abnormalities. 
At about the same time p53 was becoming a new area of 
interest 
molecular 
in cancer research, 
gene analysis 
advances in cytogenetics and 
were demonstrating· specific 
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chromosomal and submicroscopic abnormalities in association 
with various cancers. Of particular interest were the 
abnormalities associated with colorectal and lung carcinoma. 
The chromosomal changes associated with these cancers had been 
studied for years, but it was a few select experiments that 
linked these mutations to effects on the inactivation of the 
p53 gene in gliomas. 
Colorectal carcinoma 
Colorectal carcinomas appear to arise from adenomas in a 
stepwise manner. These different stages parallel the clinical 
pattern of tumor progression. Vogelstein et al. ( 1988) 
examined 172 colorectal tumor specimens, representing various 
stages of neoplastic development for four genetic alterations 
(ras-gene mutations and allelic deletions of chromosomes 5, 
17, and 18). In terms of relevance to p53, it is important to 
note that chromosome 17p sequences were lost in about seventy­
five percent of the carcinomas examined. These results 
indicate a stepwise model of colorectal tumor development in 
which both inactivation of tumor suppressor genes and 
activation of oncogenes are required for tumorigenesis. 
(Vogelstein et al., 1988). 
Kern at al. (1989) also reported specific genetic 
mutations on the short arm of chromosome 17 occurring. in 
colorectal carcinoma. In their study, colorectal carcinomas 
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from eighty-three patients were examined for molecular genetic 
alterations. Allelic deletions of specific chromosomal arms, 
including the short arm of 17 (p) and long arm of 18 (q), were 
both reported. Deletions of 17p and 18g correlated greatly 
with the development of distant metastasis and cancer-related 
death (Kern et al., 1989), possibly indicating a novel method 
of diagnosis for certain types of cancer. 
Based on these two experiments, Baker et al. (1989) were 
beginning to associate 17p deletions with p53 gene mutations 
in colorectal carcinomas, thereby arguing for a role of p53 in 
this cancer. The common area of deletion in these tumors was 
localized to a region contained within bands 17pl2 to 17p13.3, 
to which the p53 gene is mapped (Baker et al., 1989). P53 
coding regions were then analyzed from two tumors 
characterized as having allelic deletions of chromosome 17p 
and expression of large amounts of p53 mRNA from the remaining 
allele. This remaining allele was found to be mutated in each 
of these two tumors. Both mutations occurred in a highly 
conserved region of the p53 gene previously found to contain 
alterations. Baker et al. 
neoplasia might develop 
(1989) suggested that colorectal 
from' p53 gene mutations that 
inactivate a tumor suppressor function of the normal p53 gene. 
The experiment to prove the tumor suppressor function of 
p53 in colorectal carcinoma was also performed by Baker et al. 
(1990). It had been noted that in colorectal cancer, 
mutations of the p53 gene happened in coordination with a 
deletion of the remaining wild-type p53 allele. 
18 
In this 
study, wild-type and mutant human p53 genes were transfected 
into human colorectal carcinoma cell lines. Cells transfected 
with the wild-type gene formed colonies five-to tenfold less 
efficiently than those transfected with a mutant p53 gene 
(Baker et al., 1990). Carcinoma cells with the wild-type gene 
did not progress through the cell cycle. This experiment 
suggested that wild-type p53 gene can suppress the growth of 
human colorectal carcinoma cells, and a mutation in the p53 
gene product inhibits this suppressive ability (Baker et al., 
1990). 
Lung carcinoma 
As chromosomal alterations in colorectal carcinomas were 
being reported, other studies were examining chromosome 
mutations in lung carcinomas. Loss of heterozygosi ty on 
chromosomes 3, 13, and 17 in small-cell carcinoma was reported 
by Yokota et al. (1987). Five different histological types of 
lung cancers from forty-seven patients were analyzed for 
possible loss of chromosomal heterozygosity. In small-cell 
carcinomas, loss of heterozygosity on 17p was seen in five of 
five patients examined. Based on this experiment and the 
eventual mapping of the p53 gene to chromosome 17 (Nigro et 
al., 1989), subsequent work would link p53 to the development 
of lung cancer. 
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The p53 gene was specifically examined in lung cancer by 
Takahashi et al. (1989) based in part on the chromosomal 
alteration report by Yokota et al. (1987), but a correlation 
between the cytogenetics and molecular genetics would not yet 
be firmly established. In this experiment, genetic 
abnormalities of p53 were seen to include homozygous deletions 
and a variety of point or small mutations. These mutations 
changed the amino acid sequence in a highly conserved region 
of the p53 open reading frame (Takahashi et al., 1989). Also, 
low or absent p53 mRNA expression was observed in lung cancer 
cell lines as compared to that in normal lung. The work done 
in this experiment on p53 mutations, together with the 
previous reports of chromosome 17 abnormalities, would serve 
to strengthen the idea of p53 being a tumor suppressor gene. 
In 1990, Iggo et al. studied the major histological types 
of primary lung cancer for the expression of the p53 tumor 
suppressor gene. 
twenty-eight of 
Abnormalities in p53 expression occurred in 
forty 
expression of mutant 
(70%) lung carcinomas. 
p53 mRNA was found to 
Homozygous 
specifically 
contain G to T transversions resulting in mis-sense mutations 
(Iggo et al., 1990). A similar, study reported mutations of 
the p53 gene in primary, resected non-small cell lung cancer 
(Chiba et al., 1990). In this series, mutations changing the 
p53 coding sequence were found in twenty-three of fifty-one 
(40%) tumor specimens. This indicates that the p53 gene and 
chromosome 17 are important together in the tumorigenesis of 
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lung cancer, although the direct connection was not made until 
the same time as in gliomas. 
Gliomas 
Bigner et al. (1986) surveyed a large number of gliomas 
for chromosomal alterations to determine areas of primary 
gross changes in glial tumors. Karyotypic studies of 
malignant human gliomas showed the most common areas of change 
were a gain of chromosome 7 or a loss of chromosomes 10 and 
22. Other chromosomes involved in rearrangements were 1, 6, 
and 13. 
Bigner et al. (1988) continued to study human malignant 
gliomas for specific chromosomal abnormalities associated with 
this particular cancer. By karyotypic analysis of fifty-four 
malignant human gliomas (forty-three GBM), gains of chromosome 
7 and losses of chromosome 10 were seen (Bigner et al., 1988). 
Structural abnormalities of 9p and 19g were statistically 
significant as well. Despite the ongoing characterization of 
chromosomal abnormalities associated with glial tumors, no 
connection could be made with the p53 tumor suppressor gene 
because few abnormalities were detected in chromosome 17 at 
this point. 
Among the many chromosomal aberrations associated with 
gliomas, abnormalities in chromosome 17 eventually were shown 
in astrocytomas much like it had been identified in colorectal 
and lung carcinomas 
determine allelic 
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(James et al., 1989). RFLP was used to 
combinations at seven loci on human 
chromosome 17 from thirty-five patients with gliomas. Eight 
of the twenty-four (33%) tumors classified as astrocytic 
showed a loss of constitutional heterozygosity at one or more 
loci. Therefore, the homozygosity for loci on chromosome 17p 
could be associated with the development of glial tumors 
(James et al., 1989). 
Indicating that chromosomes such as 10 were not the only 
loci undergoing loss of heterozygosi ty in human malignant 
astrocytoma, chromosome 17 was further examined for 
abnormalities (Fults et al., 1989). RFLP of both AA and GBM 
showed a similar frequency of loss of constitutional 
heterozygosity on chromosome 17 at forty percent. Chromosome 
17 was becoming particularly important because of its 
relationship to p53. 
A link between chromosome 17 and the p53 gene was 
beginning to surface, as researchers realized that the loss or 
inactivation of tumor suppressor genes could play a key role 
in the onset of many human cancers, including gliomas. 
Further analysis of astrocytomas of various histological 
malignancy grades took place by means of polymorphic DNA 
markers. This method improved the accuracy of detecting 
chromosomal deletions over the standard cytogenetic technique 
of karyotyping. Potential loci containing tumor �uppressor 
genes could be determined (El-Azouzi, 1989). Chromosomal loss 
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or deletions were seen most frequently on the short arm of 
chromosome 17 (fifty percent of the tumors), and these 
deletions were observed in both low-grade and high-grade 
astrocytomas. The presence of these deletions in early stage 
tumors indicated the possible involvement of chromosome 17 in 
the initiation of tumor progression. It is important to note 
that the deletions on the short arm of chromosome 17 are 
different from the gene causing Von Recklinghausen 
neurofibromatosis (NFl), which maps to the long arm of 
chromosome 17. NFl was proposed at one time to be the leading 
candidate as the most frequently mutated "tumor suppressor 
gene" in a variety of cancers, when actually the one on the 
short arm of chromosome 17, the location of the p53 gene, 
would be more likely. 
Characterization of p53 as a Tumor Suppressor Gene 
It became apparent that the p53-encoding gene was not 
only associated with tumorigenesis of colorectal carcinoma, 
but also important in lung and brain cancers. The critical 
link between the p53 gene and the chromosome 17 alterations 
associated with a number of different cancers was a study done 
by Nigro et al. (1989}. They sought to determine whether 
tumors with allelic deletions of chromosome 17p contained 
mutant p53 genes in the allele retained, which is a 
characteristic of a tumor suppressor gene. P53 sequences of 
tumors derived from the colon, lung, brain, breast, and 
mesenchyme were analyzed. To examine p53 gene mutations, a 
1,300 base-pair (bp) fragment including the entire p53 coding 
region was generated from the complementary DNA (cDNA) using 
PCR, and this fragment was cloned and sequenced in its 
entirety (Nigro et al., 1989}. Of the nineteen tumors with 
allelic deletions of chromosome l 7p selected for sequence 
analysis, thirteen contained a single missense mutation, and 
two contained two missense mutations. Therefore, most tumors 
with one 17p allele contained a mutation of the p53 gene in 
the remaining allele. The "dominant negative" effect was 
substantiated, in which the p53 gene is mutated in the process 
of tumorigenesis, and through this effect is able to cause 
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tumor progression 
allele. In fact, 
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by inactivating the remaining wild-type 
the "dominant negative" effect may be 
mediated by binding of the mutant p53 product to the wild-type 
product, creating an inactive oligomeric complex (Nigro et 
al., 1989). The mutant allele thereby inhibits the wild-type 
allele. The wild-type product remains in the cell, however, 
and a further loss of growth control occurs when the wild-type 
allele is deleted, leaving the cell with only a mutant allele. 
Through this experiment, it was seen that most tumors with 
chromosome 17p allelic deletions contain p53 point mutations 
resulting in amino acid substitutions, and these mutations are 
also found in some tumors that have retained both parental 17p 
alleles. Also, the p53 gene mutations are "clustered" in four 
distinct "hot-spot" regions which coincide with the most 
highly conserved regions of the gene (exons 5-9) (Nigro et al., 
1989). In this way, Nigro et al. (1989) linked the many 
studies of chromosome 17 abnormalities seen in a variety of 
cancers with the p53 gene mutations also seen in numerous 
cancers. 
Incidence in Human Cancer 
Building upon this basis, two subsequent groups of 
experimenters, Levine et al. ( 1991) and Hollstein et al. 
(1991) were able to characterize the mutations of the p53 gene 
as the most common genetic change in human cancers. These 
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cancers included: colon, lung, brain, 
esophagus, reticuloendothelial tissues, 
breast, liver, 
and hemopoietic 
colon, brain, and tissues. Transitions predominated in 
lymphoid malignancies, whereas G:C to T:A transversions were 
the most frequent substitutions seen in cancers of the lung 
and liver (Hollstein et al., 1991). Four specific regions of 
the p53 protein within exons 5-9 were observed to contain the 
majority of mutations: residues 117-142, 171-181, 234-258, and 
270-286, all of which are highly conserved (Levine et al., 
1991). There are also at least three mutation "hot spots," 
affecting residues 175, 248, and 273 (Levine et al., 1991). 
Figure 1 shows the p53 open reading frame (amino acids 1-393) 
with these hot spot and conserved regions. Figure 1 also 
shows those domains specified for DNA binding versus those for 
transacti vat ion function. DNA binding occurs at the 3' 
carboxyl terminus, whereas the transacti vating function of the 
p53 protein occurs at the 5' amino end. The importance of 
these regions will become clear as each of these areas is 
discussed in subsequent sections. 
It is essential to note that particularly in cancers of 
the colon, lung, and breast, the mutation frequency rate of 
the p53 gene can reach levels of nearly seventy percent. This 
means that mutations resulting in loss of p53 function 
predispose the host to these cancers at a very high rate. 
However, in gliomas, the mutation frequency rate of the p53 
gene usually averages only about thirty percent. This is 
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consistent with the low values (forty percent) seen previously 
for the rate of loss of heterozygosity of chromosome 17p in 
gliomas (Fults et al., 1989), which maps for the p53 tumor 
suppressor gene. This suggests that the role of p53 in 
gliomas may be different than that in other cancers. 
It has been only recently that the relevance of the p53 
protein in gliomas has begun to be studied in detail. 
However, it is important to note how p53 was correlated with 
chromosomal abnormalities in other cancers such as colorectal 
and lung carcinomas before it was seen specifically in 
gliomas. This relationship to chromosomal aberrations allowed 
the p53 gene to be associated with specific cancers. 
Subsequent advances examining the characteristics of the p53 
protein allowed it to coordinately be reclassified as a tumor 
suppressor gene instead of an oncogene. This idea of tumor 
suppression had been first postulated involving the Rb gene, 
and then evidence specifically for the p53 tumor suppressor 
gene was revealed, including associated familial cancer 
syndromes. The coordination of all of these efforts directs 
the focus of p53 research into areas that demand immediate 
attention, such as the highly malignant GBM. 
Subsequent Advances in p53 Cellular Function 
Since the characterization of the p53 gene .as a tumor 
suppressor gene, several advances have been made that help 
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explain the mechanisms by which the p53 gene performs its 
function. Not all of these features apply specifically to 
gliomas, but an understanding of them aids in defining the 
role of p53 in gliomas. 
One of the first characteristics of p53 studied was its 
ability to suppress cellular growth. By developing a 
temperature-sensitive mutant of p53, the reversibility of the 
inhibition of transformation and cell proliferation was 
examined (Michalovitz et al., 1990). The temperature­
sensitive mutant, p53val135, induced transformation at 37.5°C 
while at 32.5°C, it suppressed transformation, thereby acting 
like wild-type p53 with its inhibition of proliferation of 
transformed cells. Based upon a temperature shift, the 
ability of wild-type p53 to suppress transformation is 
apparently reversible. This temperature-sensitive mutant 
could therefore be used in subsequent experiments to study the 
changing behavior of the p53 gene. 
Using the p53val135 mutant, it was shown that p53 
exhibited increased nuclear localization and decreased 
stability of the protein (Ginsberg et al., 1991). In this 
experiment, p53val135 was used ,to show arrest of cellular 
proliferation when overexpressed at 32. 5°C. At this same 
temperature, much of the p53 protein was located in the 
nucleus and the p53val135 became destabilized. At 37. 5°C 
however, the p53 protein was located primarily in the 
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cytoplasm of proliferating cells, and the p53val135 was found 
in a more stable form. These observations suggest that the 
function of p53 resides in the nucleus, and if it is removed 
from this location, it no longer functions to suppress tumor 
development. 
Regarding the exact subcellular location of the p53 
protein, Zerrahn et al. (1992) sought to further characterize 
a basis for this localization. 
temperature-sensitive p53val135, 
Previous work involved the 
as did this study in 
conjunction with the monoclonal antibody (mAb) PAb246. The 
purpose was to determine the status of the conformational 
phenotype of the p53 protein at its different locations within 
the cell. P53 was examined in four cell lines, with cellular 
phenotypes of normal (3T3), minimal transformant (T3T3), and 
maximally transformed (3T3tx, Meth A). P53 proteins in 3T3 
and T3T3 were shown to react with PAb246, thereby indicating 
a wild-type conformation, while the p53 in 3T3tx and Meth A 
cells did not bind to the PAb246, thereby signalling a mutant 
conformation. By cell fractionation, a cytoplasmic location 
of mutant p53 in 3T3tx and Meth A cells was determined, and by 
immunofluorescence microscopic analysis, 3T3 and T3T3 were 
localized to the cell nucleus (Zerrahn et al., 1992). In this 
experiment, cytoplasmic and nuclear p53 of the mutant 
phenotype bound to cellular heat shock proteins (hsp) in 
similar ratios, suggesting that hsp binding is not directly 
related to subcellular distribution of these proteins ( Zerrahn 
et al., 1992). 
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Perhaps the formation of complexes does not 
govern the location and related activity of p53, but rather 
p53 location is simply dependent on its conformational 
phenotype. 
In another study, researchers examined how mutant p53 
proteins overcome growth regulation by the wild-type p53 
allele and protein in a cell (Martinez et al., 1991). The 
exact mechanism by which the temperature-sensitive mutant 
p53val135 was detected was espoused. The conformational 
change of the p53val135 was detected by the binding of PAb246, 
which bound the wild-type or majority of p53val135 at 32.5°C, 
but did not recognize the mutant form at 39.5°C. At 39.5°C, 
the mutant p53 was localized in the cytoplasm, while at 32.5°C 
it entered the nucleus. At 32.5°C, the cells stopped 
replication and remained at the Gl/S border, accumulating in 
the Gl phase. At 37°C there was a mixture of mutant and wild­
type p53, forming a complex with the cellular heat shock 
protein hsp70 in the cytoplasm of the cell during Gl phase. 
This experiment suggests that mutant p53 proteins in 
transformed cells may sequester wild-type p53 protein in an 
hsp70-p53 complex in the cytopla'sm during the Gl phase of the 
cell cycle (Martinez et al., 1991). In this way, wild-type 
p53 is kept from its normal nuclear location and hence its 
function of tumor suppression is adversely affected. The 
"dominant negative" mechanism by which mutant p53 subverts the 
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suppressive activity of wild-type p53 has thus been partially 
substantiated, with many details yet to be explained. It has 
also been postulated that perhaps hsp70 normally binds to the 
wild-type protein alone; the hsp70 may keep it in the 
cytoplasm until its function is required, upon which it is 
unbound and enters the nucleus. If this scenario is correct, 
then the location and activity of p53 may be more dependent on 
the formation of complexes than the conformational phenotype 
as suggested by Zerrahn et al. (1992). 
Another characteristic of p53 studied in further detail 
was the exact location within the cell cycle where wild-type 
p53 growth arrest occurs. The cell cycle is divided into four 
stages, including: Gl, s, G2, and M. During Gl and G2 (gap) 
stages, very little is going on in the cell. There are two 
restriction points, or decision checkpoints, that help to 
determine the fate of the cell. One occurs at the Gl/S 
(synthesis) interphase, where the decision for the cell to 
undergoe DNA replication is made. The other is at the G2/M 
(mitosis) interphase, where the decision for cell division 
into two daugther cells is made. Lin et al. (1992) showed 
that growth arrest induced by expression of wild-type p53 
protein in a GBM cell line occurred prior to or near the 
restriction point in late Gl phase of the cell cycle. The GBM 
cell line used was T98G (the parental human line), along with 
sublines GM47.23 (a stable transfectant of T98G) and Mdel 4A. 
These contained a dexamethasone (DEX) inducible wild-type p53 
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protein which could be used to define the position in the cell 
cycle where growth suppression by wild-type p53 protein 
occurred (Mercer et al., 1990 and 1991). Also examined within 
the growth arrest stage of GBM cells was the phosphorylation 
and conformational state of wild-type p53 (Ullrich et al., 
1992) . As indicated in this study, the amount of wild-type 
p53 associated with the mutant fraction decreased as Gl arrest 
was entered. Free wild-type p53 was shown to be more 
phosphorylated than mutant p53 by two-dimensional gel 
analysis. This experiment proposes that phosphorylation leads 
to a different conformational mechanism by which wild-type p53 
acts differently from mutant p53 to induce an 
antiproliferative effect (Ullrich et al., 1992). Figure 2 
shows the effects of normal p53 and mutant p53 on the growth 
arrest stage of the cell cycle. Gradually the effects of p53 
on cells have been revealed, but there are still many areas 
which warrant consideration. As aspects such as p53 
localization in the cell and site of cell cycle arrest were 
being explored, a major focus began on the specific DNA 
binding function of p53 and the expression of its genes. 
It is already known that p53 is altered in a number of 
different cancers by a missense mutation. To better 
characterize the effects of these mutations, wild-type p53 
protein was shown to bind to a specific human DNA sequence in 
vitro (Kern et al., 1991}. To identify a sequence-specific 
binding site, cloned DNA sequences were screened by 
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immunoprecipitation techniques. By immunoprecipitation with 
mAb's against p53 (anti-p53), labelled DNA fragments bound to 
p53 were recovered. As few as 33 base pairs were needed for 
specific binding, and certain guanines within this 33-base 
pair region were essential, for a mutation of them could 
inhibit binding. Human p53 proteins with missense mutations 
could not bind to this sequence. In this way, mutations such 
as those in tumor DNA could affect the necessary binding 
affinity of p53 for specific DNA sequences (Kern et al., 
1991). 
Funk et al. (1992) initially identified transcriptionally 
active DNA-binding sites for human p53 protein and its 
complexes. It was suggested that P53 formed complexes with 
DNA directly or along with other proteins. The p53 tumor 
suppressor protein has transcriptional activation regions in 
addition to specific DNA-binding sites for p53. Based on this 
information, it is apparent that the p53 protein functions as 
a transcription factor. The specific DNA-binding sequence 
isolated was GGACATGCCCGGGCATGTCC, which promoted p53-
dependent transcription when placed upstream of a reporter 
gene (Funk et al., 1992). At this point, the complementary 
DNA-binding elements for p53 could then be determined. 
A subsequent study by Zambetti et al. (1992) identified 
the first example of a naturally occurring wild-type p53-
specific DNA-binding element that is able to mediate positive 
expression of a test gene. A 50-bp region was identified as 
35 
the p53 protein/DNA-binding element, for the 50-bp sequence 
induced wild-type p53 responsiveness on an enhancer-promoter 
region of the test gene ( Zambetti et al., 1992) . The 
importance of this experiment was to propose a method of gene 
regulation by the DNA-binding ability of wild-type p53 protein 
that is absent in the mutant p53 proteins. 
Another DNA-binding element for the wild-type p53 protein 
was the murine double minute-2 (mdm-2) gene, frequently found 
to be amplified in human sarcomas and localized to the altered 
chromosome 12q13-14 (Oliner et al., 1992). In these sarcomas, 
the human mdm-2 gene was cloned as a gene encoding a p53-
associated protein. Its exact role in the association with 
p53 was unknown, although it was suggested that it served to 
functionally inactivate wild-type p53. In this experiment, 
human mdm-2 protein was-shown to ·bind to the protein encoded 
by the human p53 gene in vitro. MDM-2 binds to p53 and upon 
amplification, it can lead to escape from p53-regulated growth 
control (Oliner et al., 1992). Further work with mdm-2 was 
done in which it was classified as a p90 oncogene and multiple 
mdm-2 proteins and mdm-2-p53 protein complexes were identified 
(Olson et al., 1993). The mdm-2 p90 protein and at least four 
other polypeptides were detected (p85, p76, p74, p58-57). Of 
these, the p90 and p58 proteins were found to form complexes 
with the p53 protein. It is suggested that the p90 mdm-2 
protein regulates p53 activity in the critical late Gl phase 
of the cell cycle (Olson et al., 1993). Therefore, mdm-2 is 
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involved in a negative feedback loop, for the p53 DNA binding 
site is upstream of mdm-2, enabling it to induce mdm-2 
expression. An overexpression of mdm-2 would cause the p53 
gene to stop transcription of this downstream effector gene. 
Also, if the mdm-2 protein is capable of functionally 
inactivating the p53 tumor suppressor gene, this could be an 
alternative to direct mutations of the p53 gene thought to be 
essential in many cancers. As noted in gliomas, there is a 
lower frequency of mutation rate, so alternatives to direct 
mutations of p53 are rapidly being introduced. In gliomas in 
particular, there is a low incidence of mdm-2 overexpression. 
At this point, the question of stimulation of p53-DNA binding 
and the mechanism of consequent tumor suppression was 
addressed. 
An important study by Price and Calderwood (1993) showed 
an increase in p53-DNA binding activity after DNA damage. An 
increase in the level of tumor-suppressor gene p53 is the 
result of a "signal" that there is DNA damage, and therefore 
the cell cycle can be arrested in Gl phase to prevent 
replication of the aberrant DNA. This "signal" is the 
critical binding of wild-type p5J to specific DNA sequences, 
which incidentally increases the half-life of the p53 protein. 
However, if there is an interruption in the cellular p53 
response to DNA damage, binding activity and the half-life of 
the p53 protein will decrease, and potentially there is 
replication of damaged DNA and consequently tumor promotion. 
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So, this experiment by Price and Calderwood (1993) proved the 
importance of DNA binding activity to p53 tumor suppressor 
function in the cell. 
Another innovative participant in the mechanism of p53 
tumor suppression appears to be the recently discovered WAFl 
gene, or wild-type p53-activated fragment 1 (El-Deiry et al., 
1993). It is essential to note that a simultaneous experiment 
localized the same product as the p21 CDK (cyclin-dependent 
kinase)- interacting protein, or Cipl (Harper et al., 1993). 
P53 specifically activates transcription of WAFl, but only wt­
p53 is capable of inducing WAFl. In the experiment, WAFl was 
localized to chromosome 6p21.2, and a p53-binding site was 
identified 2.4 kb upstream of WAFl coding sequences. WAFl 
product proves capable of suppressing the growth of human 
brain, lung, and colon tumor cells in culture. A subsequent 
experiment by the same team of researchers found the mechanism 
of WAFl action to be effective at the stages of p53-mediated 
Gl arrest and apoptosis, or programmed cell death. Induction 
of WAFl/CIPl protein took place by exposure to DNA damaging 
agents in wild-type p53-associated cells undergoing Gl arrest 
or apoptosis. Induction did, not occur in mutant p53-
containing cells or cells undergoing these processes through 
p53-independent mechanisms (El-Deiry, 1994). It had become 
clear that WAFl/CIPl, induced by p53, functions to inhibit 
cyclin-dependent kinases (CDK's). It is these cyclin­
dependent kinases that allow the cell cycle to proceed through 
the Gl phase in normal cell cycle progression. 
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So, the 
mechanism for p53 's regulation of cell proliferation relies on 
its transcription of the WAFl gene that can inhibit the CDK's, 
thereby preventing a progression of the cell cycle beyond an 
arrest at the Gl stage. Figure 3 shows the interaction of p53 
with its transcription-dependent genes mdm-2 and WAFl. In 
this way, the mechanism of p53 function is being pieced 
together, and WAFl represents an area of interest, for if this 
downstream effector is altered in some way, it affects the 
funtional activity of p53. This can occur by mechanims 
independent of p53 mutations, and could account for another 
reason why the p53 mutation rate is low in gliomas. 
Cell cycle arrest and DNA-binding activity are two of the 
many advances in the characterization of the p53 gene that 
enable it to be better applied in the treatment of gliomas and 
other cancers. Another area of interest includes the role of 
p53 in familial disposition to certain types of cancer, as the 
potential for more effective diagnosis and prognosis is 
explored. 
Familial Cancer syndromes 
Carcinogenesis is a very complex process, involving both 
environmental and host factors that can influence a person's 
susceptibility to cancer. It is important to note that with 
gliomas, there is no known environmental situation that can 
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cause or facilitate the development of primary brain 
neoplasia. In the case of lung cancer, smoking is the leading 
cause, and with skin cancer, exposure to the sun represents a 
major etiology for tumorigenesis. Despite the different 
methods of acquisition, however, there is a common bond, for 
many of these cancers are inherited disorders that can be 
detected early. In common with the Rb gene in the inheritable 
disease retinoblastoma, p53 germ line mutations appear to be 
a unique indicator of many types of cancers associated with 
familial disorders. 
One of the primary disorders that has been studied in 
relation to p53 mutations has been the Li-Fraumeni syndrome 
(LFS), a rare autosomal dominant condition characterized by 
various epithelial and mesenchymal neoplasms at diverse sites 
(Srivastava et al., 1990). originally proposed in 1969, Li 
and Fraumeni reviewed the medical r,ecords and death 
certificates of 648 childhood rhabdomyosarcoma patients and 
identified four families in which siblings or cousins had a 
childhood sarcoma, along with family histories of. breast 
cancer and other neoplasms (Malkin et al., 1990). The cancers 
specifically identified in this syndrome included: breast 
carcinomas, soft tissue sarcomas, brain tumors, osteosarcoma, 
leukemia, and adrenocortical carcinoma. Other possible 
component tumors of LFS included: melanoma� gonadal germ cell 
tumors, and carcinomas of the lung, pancreas, and prostate. 
In this way, a definition of what constituted the Li-Fraumeni 
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syndrome was constructed (Li and Fraumeni, 1969; Malkin et 
al., 1990; Srivastava et al., 1990). Eventually, p53 
mutations were used as valuable indicators of this inheritable 
disease. 
A recent study involved the analysis of the entire coding 
sequence of the p53 gene for the presence of mutations in 
twenty-one Li-Fraumeni families (Birch et al., 1994). 
Mutations were detected in seven of these families, including: 
six point mutations affecting codons 175, 180, and 220, three 
affecting codon 248, and one was a deletion/insertion mutation 
in exon 4. These seven mutations were analyzed along with 
thirty-four published examples, and the most common cancers 
occurring in the forty-one families with germline p53 
mutations and classic LFS characteristics were noted. These 
included: bone and soft tissue sarcoma, breast cancer, brain 
tumors, leukemia, and adrenocortical carcinoma (Birch et al., 
1994). Through experiments such as this, it is apparent that 
germline p53 mutations can potentially serve to identify 
asymptomatic carriers of these various cancers. However, this 
presents an ethical question as to what extent the p53 
mutations can be used to identify these carriers, for the 
relevance of these traits could have serious social 
ramifications. 
Another familial cancer syndrome associated with p53 gene 
mutations along with chromosome 17 deletions is van 
Recklinghausen neurofibromatosis (NFl). The clinical 
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manifestations of this disease include: mental retardation, 
learning disabilities, macrocephaly, and bone abnormalities. 
Characteristic of NFl is the formation of neurofibromas, which 
usually occur in the skin but may also involve deeper 
peripheral nerves and nerve roots as well as viscera and blood 
vessels innervated by the autonomic nervous system (Riccardi, 
1981). The neurofibromas are benign histologically but 
malignant transformation progresses to neurofibrosarcomas, 
which are ultimately lethal (Sorensen et al., 1986). A study 
by Menon et al. (1990) attempted to better classify the genes 
involved in this particular hereditary disorder. By direct 
sequencing of PCR-amplif ied DNA from seven neurof ibrosarcomas, 
it was found that two contained point mutations in exon 4 of 
the p53 gene. This indicated·that several genetic events were 
responsible for the tumorigenesis of NFl, and that for some 
neurofibrosarcomas inactivation of p53 appeared to be one of 
them. Table 2 summarizes some of the tumor suppressor genes 
associated with familial cancer syndromes. 
Despite the low p53 mutation rate in gliomas as compared 
to that in other cancers, the p53 gene can be used as a 
valuable indicator of the cancers associated with several 
familial diseases. And, while many of the mechanisms behind 
the involvement of p53 are unclear, its consistency in some of 
these cancers points to the usage of p53 in experimental 
procedures such as gene therapy. 
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Table 2. Summary of Tumor Suppressor Genes Associated with 
Familial Cancer syndromes 
Tumor Suppressor Familial Cancer 
Gene Syndrome 
Rb Retinoblastoma 
p53 Li-Fraumeni 
NFl Von Recklinghausen 
Neurofibromatosis 
(Neurofibromatosis 
type 1) 
Cellular 
Location/ 
Function 
nucleus/ 
transcription 
modifier 
nucleus/ 
transcription 
factor 
cytoplasm/ 
GTP­
activating 
protein 
Major 
Mutation 
deletion 
nonsense 
missense 
deletion 
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Gene Therapy 
Gene therapy is a relatively new technique involving the 
treatment of disease by the introduction of healthy genes.into 
the body (Verma, 1990). A likely candidate for this procedure 
is the p53 tumor suppressor gene, for if a wild-type p53 gene 
can be reintroduced, it may restore tumor suppressor function. 
When the wild-type p53 gene is initially inactivated, it 
usually involves a mutation of the normal gene product into a 
mutant one. Also, other regulator genes of the p53 gene such 
as mdm-2 and WAFl are adversely affected if the p53 gene is 
altered in some way. Therefore, if a normal wild-type gene is 
transfected into a cell that has undergone p53 mutations, then 
the normal p53 gene should theoretically be able to restore 
tumor suppressor function. 
Based on this hypothesis, Mercer et al. (1990) attempted 
to conditionally express human wild-type p53 and display its 
ability to negatively regulate cell growth in vitro. They 
constructed a recombinant plasmid, pM47, in which wild-type 
p53 cDNA was under transcriptional control. The pM47 was then 
introduced into the human GBM tumor cell line T98G. A stable 
clonal cell line, GM47.23, was developed that conditionally 
expressed wild-type p53 upon induction by dexamethasone. 
Results showed that induction of wild-type p53 expression by 
dexamethasone resulted in inhibition of cell cycle 
progression. The effect was reversible upon removal of 
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dexamethasone, resulting in a return to the mutant function of 
tumor promotion. More specifically, inducible wild-type p53 
was capable of inhibiting Gl progression into S phase. This 
experiment showed that wild-type p53 could indeed be 
transfected into a cell displaying a mutant characteristic, 
and could reenact the wild-type p53 gene function upon 
incorporation (Mercer et al., 1990). This proved to be a 
novel step supporting gene therapy, but the problem of gene 
delivery remained an issue to be further explored. More 
stable transfectants needed to be developed, for although 
wild-type p53 proved effective in vitro, the conditions under 
which it would work in vivo would be quite different. 
There are several methods of gene delivery that have been 
developed over the past couple of years. One such technique 
involves retroviruses, which are small (10 kb) RNA viruses 
with a single-stranded RNA genome that is converted to DNA by 
reverse transcriptase carried in the virus particle (Morsy et 
al., 1993). Another mode of gene delivery includes the 
adenoviruses such as ElA, which are large ( 38kb) double­
stranded DNA viruses. As opposed to these viral vectors, a 
recombinant construct can be used for chemical and physical 
delivery systems, in which a recombinant DNA molecule with a 
promoter and a polyadenylation signal is incorporated into a 
DNA backbone. After the most efficient methods of gene 
delivery have been demonstrated, the most effective gene for 
delivery must be defined. 
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P53 represents a unique addition to the concept of gene 
therapy. Gene therapy could prove to be a very effective 
means of treatment in cancers in which the p53 mutation rate 
is high, such as colorectal and lung. However, in cancers 
such as gliomas where the p53 mutation rate is low, the 
prospect of p53 in successful gene therapy may not be as 
applicable. Still, if even a small percentage of gliomas are 
positively affected by p53 gene therapy, then an innovative 
treatment has been introduced. Also, the exact role of p53 
and its associated genes in gliomas should be further 
elucidated so that techniques such as p53 gene therapy can be 
more effective. 
Role of p53 in Gliomas 
As more becomes known about the traits of the p53 tumor 
suppressor gene, the closer this molecule comes to having 
practical applications in a clinical sense. Specifically, 
initial studies of the mutations of the p53 gene reveal that 
it can be used as a diagnostic indicator of the malignancy 
grade of gliomas (Sidransky et al., 1992; Fults et al., 1992). 
At this time, it is essential to distinguish two lines of 
thought concerning mutations of the p53 gene. One idea 
supports the fact that mutations of the p53 gene in gliomas 
can be used for clinical applications. The other position 
maintains that the frequency rate of p53 mutations in gliomas 
is too low to be a useful indicator for this type of cancer. 
Perhaps a common theme between these two proposals is the 
progressively different molecular techniques employed to 
determine p53 gene mutations. The rationale behind both of 
these theories will be discussed in relation to one another. 
Correlation With Tumor Grade 
A decisive study of p53 mutant cells sought to determine 
their associations with brain tumor progression by cloning 
techniques (Sidransky et al., 1992). Based on the observation 
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that low-grade astrocytomas evolve into faster-growing, more 
invasive high-grade tumors (i.e. GBM), Sidransky et al. (1992) 
investigated the genetic basis for this progression. They 
found that out of four recurrent tumors studied, three of them 
had the same p53 mutation associated with the primary tumor. 
Also, progression to high-grade tumors was associated with the 
p53 gene mutation as well. They concluded brain tumors occur 
by the clonal expansion of cells that had previously acquired 
a mutation in the p53 gene, which provides them with a 
selective growth advantage (Sidransky et al., 1992). The 
basis of this experiment was Nowell's (1976) clonal evolution 
model of tumor progression. This proposed that most neoplasms 
arose from a single cell of origin and tumor progression 
sequentially resulted from acquired genetic lesions within the 
original clone (Nowell, 1976). This model of tumor cell 
genetic instability would help associate p53 mutations with 
malignancy grade, for the more aggressively developing tumor 
sublines would be the more malignant ones. 
The link between p53 mutation and loss of heterozygosity 
on chromosomes 17 and 10 was uniquely connected with 
astrocytoma progression by Fults et al. (1992), having 
originally been introduced in brain and other cancers by Nigro 
et al. (1989). The results of a sequence analysis of the p53 
tumor suppressor gene and an RFLP analysis of chromosomes 17 
and 10 were correlated in forty-five patients with cerebral 
astrocytomas at different stages. Single-strand 
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conformational polymorphism (SSCP) analysis of PCR products 
was done to detect p53 mutations in tumor DNA, and these 
mutations were confirmed by sequencing (Fults et al, 1992). 
Southern transfer analysis of somatic and tumor DNA using 
polymorphic markers was used to determine loss of 
heterozygosity. The results showed that p53 mutations were 
found in twenty-eight percent of GBM, thirty-six percent of 
AA, and none of the low-grade astrocytomas. Also, sixty-two 
percent ·of patients with loss of heterozygosity on chromosome 
17p had p53 mutations. P53 could be important in astrocytoma 
progression, for its inactivation could trigger a malignant 
transformation. 
In a related study, twenty-two human astrocytomas of WHO 
grades II and III were studied for corresponding mutations of 
the p53 gene and loss of heterozygosity on chromosome 17p (Von 
Deimling et al., 1992). 
gene (exons 5-8), SSCP 
In the conserved regions of the p53 
analysis was used to identify 
mutations, and direct DNA sequencing of PCR products was used 
to verify them. P53 mutations were found in three of eight 
grade II astrocytomas and four of fourteen grade III 
astrocytomas, and these mutations were found exclusively in 
tumors with allelic loss on chromosome 17p. - Because of the 
association of these p53 mutations with loss of heterozygosity 
of chromosome 1 7p in lower-grade astrocytomas, p53 - may be 
important in the progression of low-grade tumors and not just 
present in the high-grade ones. 
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In one study comparing p53 mutations to loss of 
heterozygosity on chromosome 17p in high-grade gliomas (WHO 
grades III and IV), there were p53 mutations in 64% of the 
tumors with one 17p allele (Frankel et al., 1992). In the 
gliomas that retained both 17p alleles, the frequency rate of 
p53 mutations was only thirty-seven percent. overall, 
mutations of the p53 gene occurred in forty percent of the 
gliomas, whereas these values were much higher in cancers of 
the lung and liver, greater than fifty and eighty percent 
respectively. 
Because of the advent of new technologies, p53 mutations 
in gliomas have been studied throughout the various malignancy 
stages. For instance, antibodies were used in conjunction 
with one another to provide more effective screening of p53 
protein expression in central nervous system tumors. Tumors 
were immunostained with the CMl polyclonal antibody (pAb) and 
the D0-7 rnAb against the p53 protein (Karamitopoulo et al., 
1993). This immunostaining with CMl pAb and D0-7 rnAb was used 
to test for abnormal p53 expression at different stages of 
malignancy (Haapasalo et al., 1993). The staining was 
positive in forty-nine percent 0£ malignant neoplasms (grades 
III and IV), and in nineteen to twenty-nine percent of grade 
II astrocytomas, while none of the grade I tumors were 
positive. P53 expression was closely correlated with 
proliferation rate, as determined by immunohistochemical 
staining of the proliferating cell nuclear antigen (PCNA). 
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Proliferation rates were higher in mutant p53 tumors because 
the PCNA only binds to mutant p53, as the wild-type p53 down-
regulates PCNA (Mercer, 1991). In this way, histologically 
similar tumors could be separated into prognostically 
different subgroups based on levels of altered p53 ·expression 
(Haapasalo et al., 1993). By measuring the amount of mutant 
p53 expression, it appears that it correlates with degrees of 
malignancy. The more malignant forms of gliomas seem to have 
more mutant p53 expressed, perhaps due to increased half-life 
and degree of phosphorylation. This correlation can be quite 
valuable clinically, for the amount of aberrant p53 expression 
can tell how far a tumor has progressed, and perhaps what 
treatments would be most effective at that juncture. Still, 
the levels of p53 mutation in gliomas are low, and that 
questions the extent to which this method of diagnosis can be 
effectively used. 
Inconsistencies in Mutation Rate 
Throughout the many studies of p53 mutations in gliomas 
using various molecular techniques, there have been many 
useful results, but a problem has persisted. Despite 
accumulation of P53 protein, the observed frequency of p53 
mutations in gliomas is lower than that of other cancers such 
as colorectal, lung, and breast. Two possibilities for the 
discrepancy have been suggested. First, the role of p53 as a 
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universal tumor suppressor gene may not be true for gliomas. 
Alternatively, malignant progression in gliomas may proceed by 
various means of functionally inactivating wild-type p53 that 
do not involve direct p53 mutations, making the glioma quite 
elusive. A number of reports have examined the low frequency 
of p53 mutations in various grades of gliomas. 
In a study by James et al. (1988), glioma malignancy 
stages were examined by restriction fragment length alleles to 
determine the genomic position of various recessive mutations. 
It was shown that the major alteration was a loss of 
constitutional heterozygosity for loci on chromosome 10 in 
twenty-eight of twenty-nine GBM. This displayed how 
chromosome 10 was the essential chromosome lost in the 
progression from grade III (AA) to grade IV (GBM) . To a 
lesser extent, restriction.fragment length alleles showed that 
sequences on chromosomes 13, 17, and 22 had been lost at 
nonrandom frequencies. It did not appear that loss of 
chromosome 17, and therefore the mapped p53 gene, was 
critical to glial tumor progression. 
Compared to the allelotype discussed earlier on human 
colorectal carcinoma (Vogelstein et al., 1989), it appeared 
that there were two different methods of allele loss by each 
type of cancer. Perhaps the tumorigenesis of colorectal 
carcinoma and malignant astrocytoma were taking place by two 
different genetic pathways, with colorectal cancers dependent 
on p53 mutations and gliomas dependent on ·loss of chromosome 
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10. This would explain the observation that p53 mutation rate 
frequency is significantly higher in colorectal carcinomas as 
opposed to gliomas. Again, much of this speculation is based 
on the current molecular techniques used at the time, and 
these have advanced along with the study of cancer. 
P53 gene mutations in human brain tumors have been 
studied by a variety of increasingly accurate techniques. 
Single-strand conformation polymorphism analysis of PCR 
products (PCR-SSCP) is a very effective method of detecting 
mutations of the p53 gene in human brain tumors (Mashiyama et 
al., 1991). Out of forty-five brain tumors analyzed, six of 
them showed mobility shifts and loss of a normal allele. 
Using direct sequencing of the six mutations, five were 
clustered in highly conserved regions of the p53 gene. 
Excluding these six mutations however, the frequency rate of 
p53 gene mutations in primary brain tumors in this experiment 
was only 9.8 percent. Despite the advancing technology of 
detecting mutations in the p53 gene, it did not appear that 
these were correlated with the malignancy of brain tumors in 
this case. 
A subsequent study using monoclonal antibodies and 
immunocytochemistry detected a higher rate of p53 mutations in 
human gliomas (Bruner et al., 1991). Because the wild-type 
p53 protein has a short half-life and is not detectable by 
this method, only the mutated p53 protein could be analyzed. 
Antibody staining for p53 protein was found in twenty-nine of 
seventy-one ( 41%) brain biopsies. 
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These values are still 
relatively low overall, and together with consistent evidence, 
it indicates that p53 may not be a universal indicator of 
malignancy grades of gliomas. 
Another experiment by Van Meir et al. 
specifically determine whether loss of 
biological function was a necessary step 
(1994) sought to 
wild-type p53 
in astrocytoma 
progression. Thirteen glioma cell lines displayed various 
amounts of p53 protein by immunoprecipitation. The cell lines 
were transfected with a plasmid construct containing a 
chloramphenicol acetyltransferase (CAT) reporter gene. The 
CAT was under the control of transcriptional elements that are 
induced by wild-type but not mutant p53. In this way, the 
expression of wild-type p53 could be detected. Four lines were 
shown to retain wild-type p53 function. In two of these cell 
lines, the wild-type p53 genotype was accompanied by a mutant 
phenotype with either the presence or absence of tumor 
development. With the inhibition of tumor development, it was 
evident that the wild-type p53 allele was still exerting its 
effect. However, with the stimulation of tumor development, 
apparently the mutant p53 allele inactivated the remaining 
wild-type p53 allele by the "dominant negative" effect. The 
observation that two cell lines conveyed a wild-type genotype 
indicated that inactivation of the p53 gene by mutation was 
not required for GBM genesis. This suggests that · the 
formation of a GBM may take place by two pathways; one that is 
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p53 mutation-dependent and the other not. Therefore, p53 
mutations are not necessarily the primary reason for glial 
tumorigenesis; rather, p53 inactivation may take place by 
alternate pathways. Table 3 summarizes the various wild-type 
and mutant p53 genotype and phenotype combinations and their 
cellular responses. 
An increasingly significant trend that has appeared 
recently in gliomas is the elevated levels of wild-type p53 
protein without p53 mutations. In an experiment by Rubio et 
al. (1993}, SSCP analysis and DNA sequencing were used to show 
absence of p53 mutations despite accumulating levels of wild­
type p53, detected by immunohistochemistry. This observation 
presents a novel situation in the case of gliomas. In other 
cancers such as colon and lung, mutations of the p53 gene are 
prominent. These mutations are predicted to be the primary 
genetic lesion in these forms of carcinomas. However, in the 
case of gliomas, mutations are not the primary genetic 
aberration, for there is accumulation of wild-type p53 without 
mutation. Therefore, there must be other mechanisms that 
cause the tumorigenesis of gliomas. For example, the binding 
of an mdm-2 product to p53 ,could form a complex that 
inactivates the p53 protein. However, in this experiment, 
mdm-2 gene amplification was not observed. For this reason, 
other participants must be examined and further testing must 
be done. Recent studies emphasize the results 0£ this 
experiment by Rubio et al. (1993}. 
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Table 3. Possible p53 Genotype and Phenotype Combinations 
and Subsequent Cellular Responses 
p53 Genotype 
1. 
wild-type 
2. 
wild-type 
3. 
wild-type 
4. 
mutant 
p53 Phenotype 
wild-type 
mutant 
mutant 
mutant 
Cellular Response 
normal (no tumor 
development) 
normal (no tumor 
development) 
tumor 
development 
in gliomas: 
Hypothesis 
wild-type 
p53 tumor 
suppression 
wild-type 
p53 
overcomes 
mutant p53 
effects 
mutant p53 
inactivates 
wild-type 
p53 
(Dominant 
Negative 
Effect) 
or 
inactivation of p53 
takes place by 
alternative factors 
such as mdm-2 or 
WAFl that can 
circumvent direct 
p53 mutations 
tumor 
development 
complete 
inactivation 
of wild-type 
p53 tumor 
suppression 
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A current report also supports the finding that p53 
mutations are low in gliomas despite accumulation of wild-type 
p53. Lang et al. (1994) found wild-type p53 protein without 
p53 gene mutation in thirty-one non-GBM gliomas (WHO grades I­
III). Immunohistochemistry detected p53 protein accumulation 
in seventy-one percent of human juvenile pilocytic 
astrocytomas (WHO grade I), sixty-three percent of 
astrocytomas (WHO grade II), and sixty-three percent of 
anaplastic astrocytomas (WHO grade III). P53 mutations were 
detected in fourteen percent of grade I, twenty-five percent 
of grade II, and nineteen percent of grade III astrocytomas. 
A total of fourteen tumors, sixty to eighty percent within 
each grade, showed p53 protein accumulation without detectable 
mutations of the p53 gene (Lang et al., 1994). Incidentally, 
no correlation between grade of astrocytoma and percentage of 
immunostained cells was observed, further indicating the 
diminishing prevalence of p53 aberrant expression as an 
indicator of malignancy grade. Also, no mdm-2 gene 
amplification was seen in these tumors. The results of this 
experiment indicated that p53 gene inactivation by mutation or 
mdm-2 complex formation was appaFently not essential for glial 
tumorigenesis. Therefore, there must be mechanisms of glial 
tumorigenesis that circumvent direct p53 mutations. 
Current estimates using loss of heterozygosity analysis 
with RFLP markers indicate that only forty percent of low- and 
intermediate-grade tumors and thirty percent of high-grade 
58 
tumors contain allelic deletions on chromosome 17p (Leon et 
al., 1994). The finding of loss of heterozygosity for alleles 
on 17p without detectable p53 mutations in some tumors further 
suggests alternatives to the direct genetic p53 involvement 
both in gliomas and other cancers. There may be a second 
tumor suppressor gene on chromosome 17p that is also affected 
in the progression to malignancy of some gliomas (Frankel et 
al. , 1992) . Perhaps other chromosomes such as 9p and 10 
(Fults et al., 1990) are involved with their own tumor 
suppressor genes, in addition to the effect of the 
amplification of the EGFR gene. P53 pathways may be bypassed 
due to the mutations in downstream effector genes (Van Meir et 
al., 1994). This statement alludes to the work already 
discussed involving the mdm-2 negative regulator of p53 in 
sarcomas (Oliner et al., 1992; Olson et al., 1993). In this 
case, mdm-2 would bind to p53 in a .complex that would not 
allow p53 to function properly. In the same way, the heat 
shock protein 70 (HSP-70) is also believed to be capable of 
binding to p53 in a complex that inactivates it, primarily by 
removing p53 from its nuclear location of function. Also, if 
the WAFl DNA sequence is mutat:ed, then the wild-type p53 
protein cannot bind and initiate transcription of the WAFl 
protein, which would inhibit CDK's and therefore cell cycle 
progression. It is also possible that alternatives to p53 
mutation may be primarily involved when applied to certain 
grades of gliomas but not all of them. These mechanisms that 
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may be responsible for affecting the function of the p53 tumor 
suppressor gene in gliomas must be discussed further. 
Alternatives Circumvent Direct p53 Mutations 
In order to better understand the mechanisms by which the 
p53 gene suppresses tumor growth, it is necessary to examine 
other co-participants in this process. As demonstrated by 
Rubio et al. (1993), Lang et al. (1994), and Van Meir et al. 
(1994), gliomas apparently have high accumulations of wild­
type p53 in addition to lack of p53 mutations. These figures 
indicate that p53 protein is important in the glial 
tumorigenesis process, but that other candidates besides 
direct p53 mutations may play a supportive role. Several 
experiments have been done to examine these indirect methods 
in closer detail, both in other cancers and gliomas. 
The binding of p53 with other cellular proteins is 
becoming an area of focus in an attempt to understand the 
mechanism of p53 tumor suppression. Perhaps these cellular 
proteins are required in some manner to allow for this 
mechanism to work properly. It,has been shown that cellular 
proteins bind to a specific conformational domain of the p53 
protein (Maxwell and Roth, 1993). In immunoprecipitation 
assays performed for lung-cancer lines, proteins of molecular 
weights 45K, 56K, and 70K in addition to others ranging from 
30K to 90K were found to be in association with the wild-type 
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p53 protein. Proteins such as these might be required to bind 
to the p53 protein in a complex that directs correct p53-DNA 
binding. As Maxwell and Roth (1993) noted, binding of the 
SV40 large T-antigen protein (Lane and Crawford, 1979) to a 
conserved, conformational domain of p53 inhibits p53's DNA­
binding and consequent transcription activation activities. 
It is a logical conclusion that cellular proteins such as this 
one could also associate with various regions of the p53 gene 
and similarly down-regulate the action of the p53 gene. 
DNA tumor viruses also exhibit examples of wt-p53 
inactivation. One method of p53 inactivation involves the 
association of human papillomavirus types 16 and 18 E6 
proteins with p53, originally shown by Werness et al. (1990). 
Human papillomavirus type 16 (HPV-16) encodes two transforming 
proteins, E6 and E7. The E7 protein binds to the Rb gene 
product, while the E6 protein has been shown here to bind to 
the cellular p53 protein. The significance of the ability of 
HPV-16 and -18 E6 proteins to form complexes with the p53 
protein was further clarified. It was shown that the E6 
oncoprotein actually promotes the degradation of p53 
(Scheffner et al., 1990). The results showed that less p53 
was present after incubation with HPV-18 E6, and no difference 
after incubation with HPV-11 E6, which does not bind to p53. 
Dominant-acting oncoproteins such as E6 could prove to be a 
vital participant in the inactivation of p53 function. 
Building upon the work of Werness et al. (1990) and Scheffner 
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et al. (1990}, HPV-16 E7 and adenovirus ElA oncoproteins were 
shown to overcome the growth arrest of cells induced by 
temperature-sensitive p53 (Vousden et al., 1993). 
Proliferation of rat embryo fibroblasts was shown to cease 
after the cells were exposed to a temperature-sensitive p53 
mutant at 33°C. Subsequently, this growth arrest was overcome 
by the expression of oncoproteins HPV-16 E7 and adenovirus 
ElA. Also, there were no detectable changes in p53 expression 
or conformation in these cells involved, showing that 
inactivation of p53 tumor suppressor function occurred without 
direct effects on p53. Overall, this experiment displays a 
plausible alternative to mutations affecting p53 function, for 
E'7 and ElA oncoproteins appear to suppress wild-type p53 
growth-suppressor activity without affecting the protein 
itself. This is different from the original coordinated 
proposa.l that p53 mutations were necessary for inactivation of. 
function. 
Another possible method of indirect tumor formation 
without p53 mutation is the presence of two oncogenes. It has 
been shown that activated oncogenes ras and myc together can 
cause carcinoma development without p53 mutation (Lu et al., 
1992). No mutations were observed in ras and myc-transformed 
mouse prostate carcinoma cells, and their growth was not 
inhibited when transfected with wild-type human p53 plasmids. 
In this scenario, it appears that carcinogenesis is occurring 
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independent of p53 mutation. Still, it does not mean that p53 
is not involved in some way, for perhaps the two oncogenes 
somehow force p53 from its location of function in the cell. 
This has not been proven, but it is possible that p53 is 
involved despite the apparent lack of p53 mutations. 
An example for cellular alternatives to frank p53 
mutation is the mdm-2 gene, which has been shown to have 
negative effects on p53 function in sarcomas. It has also 
been shown in a recent study that eight to ten percent of 157 
GBM and AA showed mdm-2 amplification and overexpression 
(Reifenberger et al., 1993). This percentage, although 
relatively small, could account for at least some of the 
remaining percentage that has been left unexplained by the low 
p 5 3 m u t a t i o n r a t e i n g 1 i o m a s . 
The results of this study showed that mdm-2 amplification was 
present in six of seventy-five GBM and three of twenty-seven 
AA (Reifenberger et al., 1993}. Although these results 
suggest that mdm-2 plays a very minor role in GBM, they open 
the possibility of as yet unidentified cellular products which 
could negatively modulate wild-type p53. 
In the p53 tumor suppressor model, it is difficult to 
consider co-factors such as mdm-2 and WAFl as completely 
independent of p53, for they too are subject to alteration. 
Upon mutation, it is quite possible that these other 
participants could affect the p53 protein in such a way that 
it would not function properly. For example, if the WAFl DNA 
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sequence was altered, a normal p53 protein could not bind and 
the WAFl protein would not be produced. In this way, 
uncontrolled cell growth would result independent of mutations 
of the normal p53 protein. Still, the p53 protein is involved 
in this situation, even though it is not directly affected. 
Lastly, an alternative that might help explain the low 
mutation rate of p53 in gliomas is that p53 is simply not 
involved to a great extent. Perhaps there are mechanisms that 
are entirely independent of p53 that account for the other 
percentage of the gliomas not accounted for under p53 's 
parameters. 
suppressor 
Suppressor 
For instance, very recently, 
gene has been isolated as the 
1 (MTSl) (Kamb et al., 1994) . 
another tumor 
Multiple Tumor 
This gene is 
localized to the short arm of human chromsome 9, and encodes 
pl6, an inhibitor of cyclin-dependent kinase 4. In this 
manner, MTSl is similar to WAFl in its cell cycle mechanism of 
tumor suppression. This MTSl could be a valuable alternative, 
but it is equally important not to abandon p53, for there are 
many of its co-participants that have not been studied in 
enough detail or possibly not even discovered yet. Also, p53 
has much higher mutation rates in other cancers besides 
gliomas, so its application may simply not be as widespread as 
originally proposed. For this reason, perhaps p53 is 
applicable to .certain cancers and tumor suppressors such as 
MTSl are better suited in other scenarios. Still, p53 remains 
the focal point of the tumor suppressor model, for it has 
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become increasingly eminent as a diagnostic indicator of 
familial cancer syndromes and as a potential candidate for 
gene therapy techniques. 
Future Research 
The p53 tumor suppressor gene is an important participant 
in a variety of cancers. Mutations of this gene produce a 
protein product that is inactive, and neoplasia results. 
Especially in cancers such as breast, colorectal, and lung, 
the high p53 mutation rate indicates that it is a primary 
target for successful tumorigenesis. Reintroduction of wild­
type p53 protein into these tumors by gene therapy techniques 
could prove to be a very effective treatment in the future. 
However, in the case of gliomas, the mutation rate is 
consistently lower. The low mutation rate of p53 in gliomas 
indicates that p53 may not be the most universal indicator of 
malignancy grades. Also, if gene therapy with normal p53 is 
successfully done in gliomas, the low mutation rate indicates 
that it may be less effective than in other cancers. It is 
always possible that p53 may not be prevalent in gliomas, but 
high protein accumulation indicates otherwise. Despite low 
mutation rate, the accumulation of wild-type p53 protein 
(Rubio et al., 1993; Lang et al., 1994; Van Meir et al.,1994) 
indicates that p53 is important -in some aspect in gliomas that 
may account for the other percentages. While needed research 
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continues on p53 gene therapy, perhaps a coordinate focus of 
p53 research should be on the other participants in the p53 
tumor suppressor model. In this way, while methods of p53 
gene therapy are explored, insight into the other co-factors 
of p53 will make the therapy that much more effective when it 
is perfected. 
Areas that warrant consideration include the various 
proteins associated with the p53 protein. It would be 
interesting to study the mechanism and timing by which the p53 
protein is shuttled from its formation in the cytoplasm to its 
function in the nucleus, and whether that mechanism is protein 
dependent or independent. In the studies of Rubio et al. 
(1993), Lang et al. (1994), and Van Meir et al. (1994), some 
of the wild-type p53 protein accumulation could have been 
detected in the cytoplasm after translation. The protein is 
normal, but perhaps there is a defect in its mechanism for re­
entry into the nucleus. Therefore, it tests normal, but its 
function cannot be exerted and tumors develop. 
Other proteins that could be studied are the ones that 
are located in the nucleus where the wild-type p53 protein 
performs its function. As postulated by Maxwell and Roth 
(1993), there may be other proteins that are required to bind 
to the p53 protein in a complex before it can bind correctly 
to DNA for transcription. These proteins may somehow be 
altered, and therefore even normal p53 cannot bind properly 
and suppress glial tumors. If this is the case, then wild-
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type p53 protein may accumulate, but it does not perform its 
function because of problems with its associated DNA-binding 
proteins. Along the same lines, there may be proteins such as 
mdm-2 that bind to the p53 protein and negatively regulate it 
so that it cannot perform its function. There may be elevated 
levels of the wild-type product, but associated proteins 
prevent the p53 protein from binding to the correct sequences 
and stopping the cell cycle. In the studies done with high 
protein accumulation with low mutation rate, there was no 
overexpression of the mdm-2 product. This does not mean that 
there are not other negative-regulator proteins of p53 that 
have not been discovered yet. 
Perhaps one of the most promising areas of p53 research 
is the effect of downstream effector genes such as WAFl. If 
the WAFl gene is mutated, then the function of the p53 protein 
cannot be executed despite normal p53 protein accumulation, 
for the p53 protein does not have a correct DNA sequence to 
bind properly. This would account for the high wild-type .p53 
protein accumulation that does not seem to be exerting its 
tumor suppressor effect. More tests should be done to 
sequence the WAFl gene, and muuation analysis would indicate 
if it was a frequently altered participant in gliomas. If so, 
this would account for the formation of tumors without p53 
gene mutations. Perhaps the WAFl gene is not mutated, but 
somehow does not interact properly with the CDK's to prevent 
cell cycle progression in response to DNA damage. All of 
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these possibilities lend support to numerous alternatives that 
could be influential in the enigmatic p53 model of tumor 
suppression in gliomas. If a gene such as WAFl is involved 
more extensively in gliomas than p53 mutations, perhaps WAFl 
could be used along with p53 in future gene therapy 
techniques. Also, there would be questions about why WAFl is 
more influential in gliomas and p53 mutations are more evident 
in other cancers. It should be noted that all of these tests 
with WAFl are based on the assumption that WAFl is the 
principal effector by which p53 affects the cell cycle. 
These are some of the many possiblities that could help 
explain the difference in p53 mutation rate and alternative 
development of tumors in gliomas. Any information obtained 
from these suggested areas of future research could be used in 
other cancers in addition to gliomas. 
Conclusion 
Tumorigenesis involves the abnormal growth of cells due 
to the interaction of two distinct processes, activation and 
inactivation. There is activation of oncogenes that allows 
for uncontrolled proliferation and inhibits differentiation. 
Equally essential, there is the inactivation of tumor 
suppressor genes that normally serve to inhibit uncontrolled 
growth and promote differentiation. One of the most important 
tumor suppressor genes currently studied is the p53 gene, 
located on the short arm of the human chromosome 17. However, 
it took many years of research for this gene to attain 
recognition for its part in the vastly changing tumorigenesis 
scheme of gliomas. 
P53 was originally postulated to be a viral protein, and 
later a nuclear oncoprotein or oncogene. Due to subsequent 
experiments and an already established tumor suppression model 
in the Rb gene, p53 began to be viewed from a different 
perspective. It became clear that the p53 gene was capable of 
such characteristics as cell cycle arrest in Gl phase of the 
cell cycle. Other characterizations such as these made the 
p53 gene a likely tumor suppressor gene candidate. However, 
it was not until it was correlated, due to advances in 
cytogenetics and molecular genetics, with chromosome 17 
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abnormalities that its true function became clear. 
Chromosomal abnormalities, specifically chromosome 17, 
had been studied for many years, beginning with colorectal 
carcinoma, lung carcinoma, and eventually gliomas. It was 
discovered that the p53 gene was located and associated with 
these same chromosome 17 aberrations. The role of p53 in a 
variety of cancers as a tumor suppressor gene became evident, 
for inactivation of this gene by mutation resulted in a 
variety of neoplasms. In fact, the mutated p53 gene product 
could be used to indicate the malignancy grade of gliomas, 
such as the difference between anaplastic astrocytomas (WHO 
grade III) and glioblastoma multiformes (WHO grade IV). 
A problem arose when experiments began to show that the 
p53 mutation rate was much lower in gliomas than in other 
types of cancers. Despite its practical applications, it 
appears that other mechanisms besides p53 mutations are 
present in gliomas, 
accumulation is high. 
the p53 gene, but it 
for the amount of wild-type protein 
These methods could be independent of 
is more likely that these are p53-
dependent mechanisms, such as the WAFl gene. Despite the 
different results of experimen�s illustrating the role of p53 
in gliomas, it is quite clear that the many aspects of p53 are 
essential to the future of cancer research, whether it be 
through familial cancer syndromes or gene therapy. The p53 
tumor suppressor gene is a leader in the evasive fight against 
cancer, especially with the alarmingly malignant glioma. 
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